The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Frohlich Tom since 2021.
This trader's CIK number is 1823925.
At the time of last reporting, Frohlich Tom was the Chief Executive Officer of Jade Biosciences, Inc.. (stock ticker symbol JBIO).
Also see all insider trading activities at Jade Biosciences, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2023 | KDNY | 0 | $0 | 8,266 | $200,569 | 15,136 | $0 |
2022 | KDNY | 0 | $0 | 11,095 | $192,520 | 20,383 | $0 |
2021 | KDNY | 0 | $0 | 60,000 | $845,372 | 48,580 | $14,700 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2025 | JBIO | 6,000 | $44,400 | 0 | $0 | 0 | $0 |
1. Chinook Therapeutics, Inc. (KDNY)
2. Jade Biosciences, Inc. (JBIO)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2023-02-10 | KDNY | Option Ex | 6,803 | .00 | 0 |
2023-02-10 | KDNY | Sale | 3,700 | 23.75 | 87,871 |
2023-01-31 | KDNY | Option Ex | 8,333 | .00 | 0 |
2023-01-31 | KDNY | Sale | 4,566 | 24.68 | 112,698 |
2022-10-06 | KDNY | Sale | 7,360 | 19.69 | 144,933 |
2022-10-06 | KDNY | Option Ex | 13,582 | .00 | 0 |
2022-02-10 | KDNY | Option Ex | 6,801 | .00 | 0 |
2022-02-11 | KDNY | Sale | 3,735 | 12.74 | 47,587 |
2021-11-10 | KDNY | Sale | 6,230 | 15.48 | 96,440 |
2021-11-05 | KDNY | Option Ex | 15,000 | .42 | 6,300 |
2021-11-05 | KDNY | Sale | 20,000 | 14.00 | 280,000 |
2021-11-08 | KDNY | Sale | 13,770 | 15.17 | 208,932 |
2021-10-06 | KDNY | Option Ex | 13,580 | .00 | 0 |
2021-09-24 | KDNY | Option Ex | 20,000 | .42 | 8,400 |
2021-09-24 | KDNY | Sale | 20,000 | 13.00 | 260,000 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-05-16 | JBIO | Buy | 6,000 | 7.40 | 44,400 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Frohlich Tom (Chief Executive Officer of Jade Biosciences, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.